MAP2K7 and melanoma: The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway, which has more or less the same functions in cells, is another metabolic pathway that is dysregulated in melanoma, although there is no FDA-approved agent that directly inhibits this pathway in melanoma, however, there are several studies showing that synthetic small molecule compounds have an effect on PI3K/AKt and/or PI3K/Akt/mTOR and the associated RAS/RAF/MEK/ERK or MAPK pathway, such as NVP-BEZ235 (53) and Rapalogs (Everolimus, Deforolimus, and Temsirolimus) (54).